Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Skin Cancer Clinical Trials

A listing of Skin Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (471) clinical trials

Clinical Trials of Texas, Inc. is conducting a research study of an investigational topical medication for dry, scaly skin caused by the sun (Actinic Keratosis.) Qualified participants receive study-related medical care from a board-certified dermatologist, study exams, evaluations and investigational medication. Eligibility Criteria: You may be eligible if you: • ...

Phase N/A

This is a clinical trial aimed to determine the best tolerated dosage of Cetuximab into arteries for the treatement of un-resectable recurrent head and neck cancer. Cetuximab belongs in a class of drugs called epidermal growth factor receptor (EGFR) inhibitors. A high percentage of head and neck cancers over-express EGFR. ...

Phase

The purpose of this study is to test the safety and tolerability of a new drug called 2141-V11 in participants who have skin lesions associated with their cancer. It will also test how the body processes the drug and whether 2141-V11 has cancer fighting activity in humans.  The study drug ...

Phase

A research study is evaluating biomarkers in blood samples from adults with untreated melanoma to assist in future diagnostic tests.  

Phase N/A

Study of Genes and Environment in Patients With Cancer in East Anglia Trent or West Midlands Regions of the United Kingdom

OBJECTIVES: - To obtain epidemiological information and biological material on a population-based series of cancer cases, including malignant melanoma, lymphoma, bladder, kidney, esophageal, and pancreatic cancer, and brain tumors. - Identify novel cancer susceptibility genes, by comparison of genotype frequencies in cases with the corresponding frequencies in large control series. ...

Phase N/A

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts: Dose Escalation and Dose Expansion. During the escalation part ...

Phase

In Vivo Real-time Detection of Circulating Melanoma Cells

Study Population: Approximately 80 subjects will be consented in order to achieve an enrollment goal of 75 subjects at this institution in three cohorts as follows: Cohort #1 will consist of fifteen healthy control subjects, ten of whom will be Caucasian and five of whom will be African-American. Subjects in ...

Phase N/A

Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma

Patients with resectable BCC will receive neoadjuvant vismodegib therapy for a time period of 12 weeks which applies to the routine use of vismodegib. This period is chosen because within this time side effects are acceptable and response is expected. Tumor examination will be performed monthly to expeditiously identify patients ...

Phase

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Using a proprietary application programming interface (API) linked to existing electronic health ...

Phase N/A

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

Liposomal formulations are frequently used today in the treatment of cancer. LiPlaCis is the first targeted liposomal formulation with a tumour triggered release mechanism to undergo clinical development in oncology and it is expected that LiPlaCis will improve the therapeutic index of cisplatin compared to conventional cisplatin. Cisplatin is one ...

Phase